The most consequential moment in Sprout Health’s refund policy is not delivery day. It is when a prescription is sent to the pharmacy. Before that transfer, the policy promises a full refund if an order is canceled or withdrawn, even after clinician review. Afterward, it calls the order nonrefundable. That makes the sequence of payment, clinical review and pharmacy transmission particularly important for anyone considering enrollment—not merely an administrative detail to revisit when a package arrives.
Sprout presents itself as a telehealth coordinator connecting patients with clinicians and pharmacies for compounded semaglutide, compounded tirzepatide and prescription NAD+. This documentary review examines its public pages consulted October 19, 2026, focusing on what customers pay for, how recurring obligations work and which organization handles problems. The documentation contains useful specifics, including cancellation deadlines and prepaid-plan refunds, but also disagreements about billing intervals, state availability and privacy. Those discrepancies warrant written clarification before payment, especially for a yearlong prepaid purchase.
At a glance
- Compounded semaglutide pricing
- $149 every four weeks, or a 12-month plan advertised as $99 per month with $1,188 paid upfront. The listing says the price is the same at any dose and includes the provider visit, medication and shipping.Sources: [4]
- Compounded tirzepatide pricing
- $199 every four weeks, or $149 per month only with a 12-month plan billed $1,788 upfront every 12 months.Sources: [4]
- Refund cutoff
- The refund policy allows a full refund before the prescription is sent to the pharmacy, but describes the order as nonrefundable after that transfer.Sources: [6]
- Cancellation notice
- Sprout must receive a cancellation request at least 48 hours before the next scheduled billing date to prevent that charge.Sources: [6]
Start with the refund boundary, not the cancel button
Sprout’s cancellation and refund policy separates ending a subscription from reversing an existing charge. Canceling before the prescription reaches the pharmacy qualifies for a complete refund, whether or not a clinician has already reviewed the request. Once the prescription has been sent for fulfillment, the policy says clinical and pharmacy resources have been committed and the order is nonrefundable. It also says prescription medications cannot be returned. Receiving nothing yet therefore does not necessarily mean the current order remains refundable.
Preventing the next charge requires a separate deadline: Sprout must receive the cancellation request at least 48 hours before the scheduled billing date. Later requests take effect the following cycle, with the upcoming charge still applying. Its older process guide uses less specific language about canceling before renewal, but that should not replace the explicit notice requirement in the cancellation policy. Our guide to cancellation notice and order status explains why those two timelines need to be tracked separately.
Prepaid plans have another provision. For early cancellation, Sprout says it divides the amount actually paid, including discounts, by the plan’s number of months, then refunds that monthly value for months of medication not yet shipped. That is a meaningful documented exit mechanism, not a promise that every annual charge is entirely refundable. The relationship between this unshipped-month provision and the pharmacy-transmission cutoff deserves clarification for an annual order, particularly if prescriptions are transmitted before individual shipments.
| Situation | Published boundary | Practical implication |
|---|---|---|
| Cancel the current order | Before prescription transmission to the pharmacy | Policy promises a complete refund before this transfer. |
| Stop the next charge | Request received at least 48 hours before billing | A later request leaves the upcoming charge in place. |
| Delay a shipment | Request at least five business days before scheduled dispatch | This is a shipment deadline, not the cancellation deadline. |
| Report contents, condition or temperature concerns | Within 24 hours of delivery | Document and report the issue promptly. |
| Report a delivered-but-missing package | Within 48 hours | Replacement is reviewed individually, not automatic. |
The advertised monthly figures do not all describe monthly payments
The homepage offers compounded semaglutide at $149 every four weeks, alongside a 12-month alternative advertised as $99 per month with $1,188 collected upfront. It states the same price applies at any dose and includes the provider visit, medication and shipping. Compounded tirzepatide is listed at $199 every four weeks; its $149 monthly figure applies only to a 12-month plan billed $1,788 upfront every 12 months. The plans renew until canceled. Annual prepayment is an alternative, not a requirement for every customer.
A four-week billing cycle is not a calendar month. More importantly, the refund policy describes recurring monthly, three-month or six-month subscriptions and says the payment method is charged each month until paused or canceled. Those descriptions do not neatly match the homepage’s four-week and annual choices. The checkout schedule therefore needs explicit confirmation. Our explanation of billing intervals and commitments is useful here: an advertised monthly equivalent does not establish the actual collection date or the amount collected at renewal.
The terms say checkout prices include the mandatory doctor consultation and treatment services. Nevertheless, the public documentation does not establish annual shipment timing, medication quantities, insurance acceptance, insurer reimbursement or HSA/FSA eligibility. It also does not specify the administration route or presentation of these products. Sprout separately advertises compounded prescription NAD+, identified as nicotinamide adenine dinucleotide, starting at $199; that price block does not establish a supply period or commitment. None of these gaps should be filled by assumptions drawn from the headline price.
Enrollment involves a clinical decision, not a medication guarantee
The current homepage describes a short online assessment covering health history and goals, followed by review by a state-licensed medical provider who decides whether treatment is clinically appropriate. The terms identify the business as Sprout Health Partners LLC and restrict website use and registration to adults 18 and older. They expressly warn that consultation does not guarantee approval: clinicians may decline the requested treatment or modify the plan according to their clinical judgment.
Sprout’s detailed older guide describes a more visibly staged purchase process. A successful preliminary quiz only prequalifies someone to buy; a fuller medical questionnaire follows payment. A licensed clinician then determines whether prescribing is appropriate, and the guide says an unqualified customer’s order is canceled and refunded. Because Sprout expressly identifies these instructions as legacy material, they should not automatically be treated as the current workflow. Before paying, establish which questionnaire triggers clinical review and whether payment precedes that review.
Geography is a substantial unresolved enrollment issue. The terms exclude Alabama, Arkansas, Mississippi, Louisiana, California and North Dakota, while the privacy policy claims service in all 50 states. The terms also list Arkansas among 15 states receiving synchronous MDI visits, despite excluding it elsewhere. That list additionally names Colorado, Idaho, Illinois, Indiana, Maryland, Missouri, Montana, Nebraska, New York, Oklahoma, South Dakota, Vermont, Virginia and Wisconsin. These statements do not establish actual availability for a particular treatment; residents need a current, treatment-specific answer.
The platform, prescriber and pharmacy have separate responsibilities
Sprout says it coordinates care rather than manufacturing drugs or operating as a pharmacy. A licensed clinician makes prescribing decisions, and a state-licensed pharmacy prepares an approved prescription. The terms identify MD Integrations, or MDI, as a physician-only clinical network collaborating with the platform. These are the provider’s descriptions, not independently verified credentials. Separating the organizations matters because a billing dispute, a prescribing question and a dispensing concern do not necessarily belong with the same support team.
The terms list Foothills Pharmacy and Promise Pharmacy as external-service contacts, but do not assign particular products to either. They give rx@foothillspharmacy.com and info@promisepharmacy.com, plus support@mdintegrations.com for MDI. The homepage says an approved prescription goes to a partner pharmacy unless the patient specifies another licensed pharmacy of their choice. That option does not, by itself, explain whether choosing another pharmacy changes package pricing, shipping arrangements or how the medication portion is paid.
For an individual order, ask for the actual dispensing pharmacy’s name, contact details and complete formulation before assuming a listed partner will handle it. The consulted documentation does not establish which pharmacy prepares each product or independently verify its credentials. Our guide to platform, clinician and pharmacy responsibilities provides a useful framework for organizing those questions. Sprout’s coordination role is documented; a guarantee that one organization controls every step is not.
Shipping promises describe stages, not a guaranteed arrival date
The homepage says most prescriptions are sent to the pharmacy within two business days after completion of the visit. That is a prescription-transfer estimate, not an arrival promise. The legacy guide separately says orders typically ship within three to seven business days after prescribing and transmission to a partner pharmacy. Dispatch still is not delivery. Sprout describes discreet home delivery from state-licensed U.S. pharmacies, but the consulted documentation provides no guaranteed arrival deadline.
The legacy process promises tracking by email and in the customer portal after shipment. The refund policy allows shipment-delay requests through help@joinsprouthealth.com or the patient portal, requiring at least five business days before scheduled dispatch to guarantee action. During a shortage, its stated standard practice is to wait for stock and fulfill the order rather than issue a refund. Someone depending on a specific delivery window should therefore establish both the dispatch schedule and what happens financially if fulfillment stalls.
Delivery complaints carry short reporting windows. Contents, condition or temperature-integrity concerns must be reported within 24 hours; confirmed damage or defects on arrival qualify for a no-cost replacement under the policy. Packages marked delivered but not received must be reported within 48 hours, with replacement decided case by case. A later passage mixes 48-hour and 72-hour references and warns replacement may cost extra. Separately, FDA advises not using an injectable GLP-1 product that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy.
Renewal payment and clinical follow-up are separate events
In the legacy workflow, each rebill generates a new medical questionnaire so the clinician can assess progress and possible side effects. The next shipment depends on completing that questionnaire and receiving another approved prescription. This description is useful because it shows that a recurring charge need not mean a shipment is already authorized. However, the public documentation does not establish whether every current plan uses that exact sequence or explain how annual-plan billing aligns with each clinical reassessment.
Sprout directs side-effect concerns and medical questions to the licensed clinician through the patient account or medical portal. Administrative support explicitly cannot provide medical advice. General support is available at help@joinsprouthealth.com or +1 (833) 496-4020, Monday through Friday, 9:00 a.m. to 5:30 p.m. Mountain Time. Those published hours do not establish a guaranteed response time, round-the-clock clinical coverage or a promise that every message will receive an immediate answer.
Account access also depends on purchase timing. The contact page directs orders from July 2026 onward to a patient account for tracking, plan management and care-team messaging. Earlier orders use a customer portal for order status, tracking and subscription details. This split makes it particularly important for existing customers to identify the applicable portal and terms. Keep the billing date, clinical-review status and scheduled shipment date separately recorded rather than treating the portal’s subscription status as proof that all three are synchronized.
Privacy language needs reconciliation before sensitive information is entered
The terms say the site is not designed to comply with industry-specific regulations, including HIPAA, and instruct people not to use it for interactions requiring such compliance. The legacy guide, by contrast, describes the company as fully HIPAA compliant and says shared information is encrypted and inaccessible outside the care team. These are materially different representations. Their coexistence does not support an independent conclusion either that every interaction is protected in the same way or that Sprout violates privacy law.
The privacy policy offers a narrower distinction: when an established patient relationship exists, authenticated portions of the websites, applications and interactions are governed by a HIPAA Notice of Privacy Practices. That notice was not available within the consulted documentation, so its scope could not be assessed. A prospective customer should ask which organization receives the initial questionnaire, when the patient relationship begins and which notice governs information entered before signing into the clinical account.
The homepage footer also contemplates operational and marketing use of information, including hashed or de-identified data for audience targeting and exclusion on platforms such as Google and Meta. This language should be read alongside—not erased by—the clinical privacy statements. The most useful preparation is to obtain the applicable notices and distinguish public-site activity from authenticated care interactions. The enrollment-terms checklist can help organize these requests without assuming that a general privacy assurance resolves every data-use question.
A clear contract would still not establish clinical performance
Sprout discloses that its compounded semaglutide and tirzepatide are not FDA approved and have not been evaluated by FDA for safety, effectiveness or quality. It also says they are neither brand-name drugs nor generics. The NAD+ listing carries its own nonapproval disclosure. These product descriptions matter independently of subscription terms: an included consultation, a named pharmacy or a detailed refund policy does not convert a compounded preparation into an FDA-approved product.
FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence, and it does not independently validate or condemn Sprout. The documentation also leaves the products’ routes, full formulas and presentations unspecified. Readers should clarify those details with the prescriber and pharmacist rather than importing assumptions from studies or advertising about other products.
The remaining practical questions are specific: What exactly is being prescribed? Why is that preparation appropriate? Which pharmacy will dispense it? What clinical follow-up is included, and how does it interact with renewal? FDA has reported measurement and administration errors involving compounded medication, some associated with hospitalization, making clear professional instructions important. This review cannot supply dosing instructions or establish Sprout-specific treatment outcomes. Contract clarity helps define service obligations; it cannot substitute for an individualized clinical evaluation.
Questions & answers
Does Sprout require an annual upfront payment?
Not for every advertised option. The homepage lists compounded semaglutide at $149 every four weeks and compounded tirzepatide at $199 every four weeks. The lower advertised monthly equivalents require annual prepayment: $1,188 for semaglutide or $1,788 for tirzepatide. Confirm the selected checkout schedule because the refund policy describes different subscription intervals.
Can I get a refund after a clinician approves treatment?
The policy allows a full refund after clinician review if the prescription has not yet been sent to the pharmacy. Approval itself is not the stated cutoff; pharmacy transmission is. Once transmission occurs, the current order is described as nonrefundable. Prepaid plans also have a separate provision for months not yet shipped, whose application should be confirmed for the specific order.
How early must I cancel or request a shipment delay?
To prevent the next charge, Sprout must receive cancellation at least 48 hours before the scheduled billing date. To guarantee it can act on a shipment-delay request, the policy requires at least five business days before scheduled dispatch. These are different deadlines. Requesting a delay should not be assumed to cancel the subscription or reverse a charge.
Can I choose a pharmacy instead of using Sprout’s partner?
The homepage says patients may specify a different licensed pharmacy. The terms name Foothills Pharmacy and Promise Pharmacy as external contacts without assigning products to them. The documentation does not resolve how outside-pharmacy selection affects the advertised package price or shipping. Ask for written confirmation of the dispensing arrangement and charges before relying on that choice.
What should I do about a damaged, warm or missing delivery?
Sprout requires contents, condition and temperature concerns within 24 hours of delivery; delivered-but-missing packages must be reported within 48 hours. Missing-package replacement is not automatic, and later-claim language is inconsistent. FDA separately advises not using an injectable GLP-1 drug that arrives warm or insufficiently refrigerated and contacting the provider or dispensing pharmacy to resolve the concern.
Who handles treatment questions and subscription problems?
Medical questions belong with the licensed clinician through the patient account or medical portal; administrative support cannot give medical advice. For general support, Sprout publishes help@joinsprouthealth.com and +1 (833) 496-4020 during weekday Mountain Time business hours. Orders from July 2026 onward and earlier orders use different account systems, so start with the access route matching the purchase date.
Our assessment
Sprout provides more concrete contractual detail than a headline price alone: it identifies a pharmacy-transfer refund cutoff, a 48-hour cancellation deadline, shipment-delay notice and a method for refunding unshipped months on prepaid plans. Its published four-week prices also give customers an alternative to annual prepayment. The weakness is consistency. Billing schedules, state availability, privacy representations and delivery-claim deadlines do not fully align across the consulted pages, and the legacy/current account split complicates interpretation. Before enrolling, obtain written confirmation of the exact product, payment schedule, renewal date, pharmacy, refund rules and applicable privacy notice. Sprout’s documentation supports describing a telehealth coordination service offering compounded prescriptions—not guaranteed prescribing, verified clinical outcomes or an uncomplicated promise that cancellation returns every payment.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.